Location History:
- Madrid, ES (2008)
- Alcobendas, ES (2010)
Company Filing History:
Years Active: 2008-2010
Title: The Innovative Mind of Frederic Laurent Cordier
Introduction
Frederic Laurent Cordier is a notable inventor based in Alcobendas, Spain, known for his contributions to the field of pharmaceuticals. With a focus on advancing treatments for obesity and related diseases, Cordier holds two patents that reflect his innovative spirit and dedication to research.
Latest Patents
One of Cordier's latest inventions involves MCH receptor antagonists. This patent describes a melanin concentrating hormone antagonist compound that serves as a potential treatment for obesity and its associated symptoms. The compound is defined by its specific chemical formula and includes pharmaceutically acceptable salts, solvates, and enantiomers.
Another significant patent by Cordier pertains to AMPA receptor potentiators. This invention outlines formulations that comprise AMPA receptor potentiators and details methods for their use, alongside the intermediates useful for their preparation. Through these inventions, Cordier emphasizes the importance of developing effective therapies for pressing health issues.
Career Highlights
Frederic Laurent Cordier currently works at Eli Lilly and Company, a prominent player in the pharmaceutical industry. His role there has allowed him to further his research and significantly contribute to the development of innovative therapies that have the potential to impact many lives.
Collaborations
Throughout his career, Cordier has collaborated with esteemed colleagues, including Esteban Dominguez-Manzanares and Ana Maria Castano Mansanet. These partnerships have enriched his research endeavors and have been vital in advancing the innovative solutions stemming from their collective expertise.
Conclusion
Frederic Laurent Cordier exemplifies the spirit of innovation within the pharmaceutical industry. His patents on MCH receptor antagonists and AMPA receptor potentiators highlight his commitment to addressing critical health challenges. As he continues his work at Eli Lilly and Company, Cordier's contributions are surely paving the way for future breakthroughs in medical science.